doi.bio/isomorphic_labs
Isomorphic Labs
Summary
Isomorphic Labs is a London-based company that uses artificial intelligence for drug discovery. The company was founded by Demis Hassabis, who also serves as its CEO. Isomorphic Labs was established as a spin-off from Alphabet Inc.'s AI research lab, DeepMind, which Hassabis also founded and currently heads.
The company leverages DeepMind's AlphaFold technology to predict protein structures and molecule interactions in the human body, enabling researchers to identify new target pathways for drug delivery. Isomorphic Labs aims to revolutionize the drug discovery process by utilizing an AI-first approach, ultimately seeking to understand the fundamental mechanisms of life.
People
Demis Hassabis Joshua Bambrick Alexey Cherepanov Miles Congreve Caroline M R Low Pascal Savy Adrian Stecula Catherine Tong Sergei Yakneen Max Jaderberg
History
Isomorphic Labs was incorporated on February 4, 2021, and officially announced on November 5, 2021. In December 2022, the company expanded its operations by establishing a second office in Lausanne, Switzerland.
Partnerships and Collaborations
In January 2024, Isomorphic Labs formed partnerships with prominent pharmaceutical companies Novartis AG and Eli Lilly and Company. These collaborations focus on AI drug discovery and research, with the potential to be worth nearly $3 billion, excluding future drug sales royalties.
Technology
Isomorphic Labs builds upon DeepMind's AlphaFold technology, specifically utilizing AlphaFold 3. This AI model can predict the structure and interactions of various molecules involved in biological processes, including proteins, DNA, RNA, and drug-related chemicals. AlphaFold 3 represents a significant advancement over its predecessor, AlphaFold 2, by expanding its capabilities beyond just protein structure prediction.
Key People
- Demis Hassabis: Founder and CEO of Isomorphic Labs. He is also the founder and CEO of DeepMind.
- John Jumper: Senior researcher at DeepMind who leads the protein structure team. He played a crucial role in developing AlphaFold 2 and AlphaFold 3.
- Colin Murdoch: The first President of Isomorphic Labs. He previously served as Chief Business Officer at DeepMind and led the AlphaFold translation and application team.
- Max Jaderberg: Chief AI Scientist at Isomorphic Labs.
- Sergei Yakneen: CTO of Isomorphic Labs.
- Mene Pangalos: Scientific Advisory Board member. He brings extensive experience in biopharmaceutical research and development from his time at AstraZeneca.